ClinicalTrials.gg
CompletedNCT06389942Updated Dec 27, 2024

Single Ascending Dose Study of 9MW3011 in Chinese Healthy Subject

A Phase 1 interventional study of 9MW3011 and 9MW3011 placebo in Healthy, sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2023, registered Feb 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objectives of the study are to evaluate the safety , tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of single ascending intravenous (IV) doses of 9MW3011 in Chinese healthy volunteers.

Read the detailed description

The single ascending dose(SAD) study will comprise 6 dose cohorts of 8 healthy volunteers each. In each cohort, subjects will be randomized in a 6:2 ratio to receive 9MW3011 or placebo via intravenous infusion.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Mabwell (Shanghai) Bioscience Co., Ltd. is the lead sponsor of 54 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 65 years (including 18 and 65 years).
  2. Weight≥50.0 kg for males, or weight≥45.0 kg for females, and (BMI) in the range of 19.0 \~ 26.0 kg/m2 (including cut-off value).
  3. Being judged by the investigator to be eligible based on medical history, physical examination, laboratory tests and test related items of inspection or no mild abnormalities.
  4. Volunteered to participate in this clinical trial, capable of giving written .

Exclusion criteria

Exclusion Criteria:

  1. Nervous/mental, respiratory system, cardiovascular system, digestive system, blood and lymphatic system, endocrine system, skeletal and muscular system , immune system, urinary system diseases , or a family history of severe systemic diseases (including cardiovascular system, digestive system, urinary system, etc.), may affect the health status of the subjects or any other diseases and physiological conditions that may affect the results of the study , judged by the investigator.
  2. Currently suffering from iron deficiency/Iron deficiency anemia, taking iron supplements and complicated with other diseases related to abnormal iron metabolism.
  3. Subjects who have a history of allergies to monoclonal antibodies or any drug components; those who have a history of allergies to of 9MW3011.
  4. Subjects who have lost blood or donated blood ≥200mL within 3 months before screening, or those who plan to donate blood within 3 months.
  5. Positive for virus surface antigen and/or hepatitis B virus e antigen, virus antibody, antibody, or treponema pallidum antibody.
  6. Subjects who is inappropriate to participate in the trial due to any reasons as determined by the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    9MW3011 Dose 1

    Ascending IV doses administered per protocol

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    9MW3011 Dose 2

    Ascending IV doses administered per protocol

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    9MW3011 Dose 3

    Ascending IV doses administered per protocol

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    9MW3011 Dose 4

    Ascending IV doses administered per protocol

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    9MW3011 Dose 5

    Ascending IV doses administered per protocol

    Drug: 9MW3011 · Drug: 9MW3011 placebo

  • Experimental
    9MW3011 Dose 6

    Ascending IV doses administered per protocol

    Drug: 9MW3011 · Drug: 9MW3011 placebo

Interventions

  • Single dose intravenously on day 1

  • Drug9MW3011 placebo

    Single dose intravenously on day 1

06

What researchers measure

Primary outcomes

  1. Adverse Event(including serious adverse event)

    The incidence of AEs and SAEs from treatment until the last scheduled follow-up visit

    Time frame: up to day 99

Secondary outcomes

  1. Number of subjects with abnormal vital signs

    Vital signs measurements will include pulse rate, respiration rate, blood pressure (systolic and diastolic blood pressure) and body temperature.

    Time frame: up to day 99

  2. Number of subjects with abnormal clinically significant results from physical examination

    The physical examinations will include examination of the following: skin and mucous membranes, lymph nodes, head and neck, chest, abdomen, musculoskeletal, nervous system, and other sites of note elicited from the subject.

    Time frame: up to day 99

  3. Number of subjects with abnormal clinically significant 12-lead electrocardiogram (ECG) parameters

    The examination indicators include heart rate, PR, QRS, uncorrected QT, and QTcF(corrected by Fridericia formula).

    Time frame: up to day 99

  4. Number of subjects with abnormal clinically significant clinical laboratory results

    Clinical laboratory tests include hematology, urinalysis, blood chemistry, coagulation function.

    Time frame: up to day 99

  5. Cmax

    The peak concentration

    Time frame: up to day 85

  6. AUC0-t

    The area under the concentration-time curve from zero to the last time point

    Time frame: up to day 85

  7. AUC0-∞

    The area under the concentration-time curve from zero to infinity

    Time frame: up to day 85

  8. Tmax

    The time to reach peak concentration

    Time frame: up to day 85

  9. λz

    Terminal elimination rate constant

    Time frame: up to day 85

  10. t1/2z

    The terminal elimination half-life

    Time frame: up to day 85

  11. Vz

    The volume of distribution

    Time frame: up to day 85

  12. CL

    Clearance

    Time frame: up to day 85

  13. MRT

    Mean residence time

    Time frame: up to day 85

  14. Pharmacodynamic(PD)parameters-hepcidin

    Change from baseline in hepcidin levels

    Time frame: up to day 85

  15. PD parameters-serum iron

    Change from baseline in serum iron levels

    Time frame: up to day 85

  16. PD parameters-TSAT

    Change from baseline in transferrin saturation(TSAT) levels

    Time frame: up to day 85

  17. Anti-drug antibodies(ADA)

    The incidence of ADA

    Time frame: up to day 85

07

Study locations

1 site
  • PKUcare Luzhong Hospital
    Zibo, Shandong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in May 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2024
First posted
Apr 29, 2024
StartActual
Mar 10, 2023
Primary completionActual
May 31, 2024
CompletionActual
May 31, 2024
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06389942
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Mar 10, 2023
Primary completion
May 31, 2024
Completion
May 31, 2024
Last update
Dec 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-TMPRSS6 Monoclonal Antibody DISC-3405

Start the discussion